Erbitux monoclonal antibody treatment along with 6 weeks of radiation was approved by the FDA for Head and Neck cancer in 2016. Last week I received my first infusion without side effect and I started radiation yesterday, again without side effect. The goal is to prevent recurrence of SCC that was removed from my lower lip with Mohs surgery. The surgeon reported clear margins, but the team is concerned about potential recurrence because of the cancer proximity to nerves and muscle. That proximity presents a rate of recurrence estimated around 25-30%.

Of course, prior to treatment, I received a long list of possible negative reactions and I'm sure they "throw in the kitchen sink" because they can't know how different patients react. So far I've experienced nothing bad.

I will report back on the progression of the treatment and what I experience.